https://scholars.lib.ntu.edu.tw/handle/123456789/561110
標題: | Clinical features, antimicrobial susceptibilities, and outcomes of Elizabethkingia meningoseptica (Chryseobacterium meningosepticum) bacteremia at a medical center in Taiwan, 1999-2006 | 作者: | Hsu M.-S. Liao C.-H. YU-TSUNG HUANG Liu C.-Y. Yang C.-J. Kao K.-L. PO-REN HSUEH |
公開日期: | 2011 | 卷: | 30 | 期: | 10 | 起(迄)頁: | 1271-1278 | 來源出版物: | European Journal of Clinical Microbiology and Infectious Diseases | 摘要: | A total of 118 patients with Elizabethkingia meningoseptica bacteremia at a medical center in Taiwan from 1999 to 2006 were studied. Minimum inhibitory concentrations (MICs) of 99 preserved isolates were determined. The incidence (per 100,000 admissions) of E. meningoseptica bacteremia increased from 7.5 in 1996 to 35.6 in 2006 (p = 0.006). Among them, 84% presented with fever, 86% had nosocomial infections, and 60% had acquired the infection in intensive care units (ICUs). The most common underlying diseases were malignancy (36%) and diabetes mellitus (25%). Seventy-eight percent of patients had primary bacteremia, followed by pneumonia (9%), soft tissue infection, and catheter-related bacteremia (6%). Forty-five patients (38%) had polymicrobial bacteremia. Overall, the 14-day mortality was 23.4%. Multivariate analysis revealed E. meningoseptica bacteremia acquired in an ICU (p = 0.048, odds ratio [OR] 4.23) and presence of effective antibiotic treatment after the availability of culture results (p = 0.049, OR 0.31) were independent predictors of 14-day mortality. The 14-day mortality was higher among patients receiving carbapenems (p = 0.046) than fluoroquinolones or other antimicrobial agents. More than 80% of the isolates tested were susceptible to trimethoprim-sulfamethoxzole, moxifloxacin, and levofloxacin. The MIC 50 and MIC 90 of the isolates to tigecycline and doxycycline were both 4 μg/mL and 8 μg/ml, respectively. ? 2011 Springer-Verlag. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/561110 | ISSN: | 0934-9723 | DOI: | 10.1007/s10096-011-1223-0 | SDG/關鍵字: | aminoglycoside; carbapenem derivative; ciprofloxacin; cotrimoxazole; doxycycline; levofloxacin; moxifloxacin; penicillin derivative; piperacillin plus tazobactam; quinoline derived antiinfective agent; tigecycline; timentin; aged; antibiotic sensitivity; article; bacterium culture; bacterium isolation; catheter infection; Chryseobacterium meningosepticum; clinical article; clinical feature; controlled study; diabetes mellitus; disease association; female; Gram negative sepsis; hospital infection; human; male; minimum inhibitory concentration; nonhuman; outcome assessment; pneumonia; prediction; primary infection; priority journal; retrospective study; soft tissue infection; Taiwan; Academic Medical Centers; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; Child; Child, Preschool; Chryseobacterium; Cross Infection; Diabetes Complications; Female; Flavobacteriaceae Infections; Humans; Incidence; Male; Microbial Sensitivity Tests; Middle Aged; Neoplasms; Risk Factors; Survival Analysis; Taiwan; Treatment Outcome; Young Adult |
顯示於: | 醫學院附設醫院 (臺大醫院) |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。